Jones Jamal T, deCastro B Rey, August Euna M, Smith Dawn K
Division of HIV/AIDS Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Rd, Mail Stop US8-4, Atlanta, GA, 30333, USA.
Division of HIV/AIDS Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, 30333, USA.
AIDS Behav. 2021 Apr;25(4):1267-1275. doi: 10.1007/s10461-020-03089-5. Epub 2020 Nov 17.
Few studies have assessed providers' intent of prescribing PrEP in the future. We analyzed cross-sectional web-based surveys to estimate trends from 2016 to 2020 in PrEP awareness and prescribing behaviors in the United States among primary care providers. Multivariable logistic regression was used to estimate prevalence of PrEP awareness, prescribing behaviors, and likelihood of prescribing PrEP in the next 12 months. The adjusted prevalence for PrEP awareness was significantly higher in 2019 (93.7%, 95% CI 91.9%, 95.2%) compared to 2018 (88.1%, 95% CI 85.5%, 90.3%). The adjusted prevalence for prescribing PrEP was significantly higher in 2019 (16.4%, 95% CI 13.6%, 19.6%) and 2020 (15.6%, 95% CI 13.0%, 18.7%) compared to 2018 (12.2%, 95% CI 10.0%, 14.7%). Practicing in the West and regularly screening for HIV were associated with higher PrEP awareness and provision. Studies should examine factors associated with PrEP provision for groups with increased risk for HIV.
很少有研究评估医疗服务提供者未来开具暴露前预防（PrEP）药物的意愿。我们分析了基于网络的横断面调查，以估计2016年至2020年美国初级保健提供者中PrEP知晓率和开药行为的趋势。使用多变量逻辑回归来估计PrEP知晓率、开药行为的流行率以及在未来12个月内开具PrEP药物的可能性。与2018年（88.1%，95%置信区间85.5%，90.3%）相比，2019年PrEP知晓率的调整后流行率显著更高（93.7%，95%置信区间91.9%，95.2%）。与2018年（12.2%，95%置信区间10.0%，14.7%）相比，2019年（16.4%，95%置信区间13.6%，19.6%）和2020年（15.6%，95%置信区间13.0%，18.7%）开具PrEP药物的调整后流行率显著更高。在西部执业且定期进行HIV筛查与更高的PrEP知晓率和提供率相关。研究应检查与HIV感染风险增加群体的PrEP提供相关的因素。
AIDS Patient Care STDS. 2020-2-28
J Law Med Ethics. 2022
Zotero 插件